The authors say the study underscores the importance of adequate drug-susceptibility testing capacity.
The decision means generic versions of the drug, which is a critical part of shorter regimens for drug-resistant TB, can be made and sold in 134 low- and middle-income countries.
Although progress has stalled, world leaders at today's UN high-level meeting will commit to new targets aimed at reducing TB incidence and deaths.
The deal is expected to make 5 million more tests available, improving access for lower- and middle-income countries.
The authors said the case report provides a cautionary example for health providers in areas with low TB incidence.
The price cut for bedaquiline will enable low- and middle-income countries to buy more WHO-recommended treatment regimens for drug-resistant TB.
EU countries reported 33,527 TB cases in 2021, which continues a downward trend observed since 2002.
Scaling up preventive TB treatment for people with HIV/AIDS and household contacts of newly diagnosed TB patients could save nearly 850,000 lives by 2035, experts estimate.
The agreement between Johnson & Johnson and the Stop TB Partnership will make cheaper, generic versions of bedaquiline available in low- and middle-income nations.
The first clinical trial of a 3-month treatment regimen for tuberculosis is closing enrollment because of a high rate of unfavorable outcomes.